Within 5 years of a breast cancer diagnosis, patients are at an increased risk of developing thyroid cancer, according to a new study, which was presented at the Endocrine Society's 97th annual meeting.
Within 5 years of a breast cancer diagnosis, patients are at an increased risk of developing thyroid cancer, according to a new study, which was presented at the Endocrine Society’s 97th annual meeting in San Diego on March 5-8.
The study identified 704,402 patients with only breast cancer, 49,663 patients with only thyroid cancer, and 1526 patients who developed thyroid cancer after breast cancer. Women who developed thyroid cancer after their breast cancer diagnosis tended to be younger when their breast cancer was diagnosed when compared with women with breast cancer alone.
Breast cancer survivors who developed thyroid cancer were more likely to have a more aggressive type of thyroid cancer compared with patients who only had thyroid cancer, but their cancers were smaller in size.
“Recognition of this association between breast and thyroid cancer should prompt vigilant screening for thyroid cancer among breast cancer survivors,” said lead investigator Jennifer Hong Kuo, MD, assistant professor of surgery at Columbia University, New York City.
She recommended that breast cancer survivors receiving counseling about their risk of thyroid cancer. Next, Dr Kuo plans to study if tamoxifen treatment, which is typically given for 5 years after a breast cancer diagnosis, increases the risk of thyroid cancer.
This is not the first time an association between breast and thyroid cancers has been identified; however, the relationship has been controversial because prior studies were largely based on single-institution studies. The study presented at ENDO 2015 was based on an analysis of the National Cancer Institute’s Surveillance, Epidemiology, and End Results 9 (SEER 9) database, which includes data from 1973.
In 1984, a study using the Connecticut Tumor Registry identified an elevated risk of thyroid cancer following breast cancer. However, the study population consisted of just 1618 women with primary thyroid cancer and 39,194 women with primary breast cancer. The researchers determined that 34 thyroid cancer patients later developed breast cancer and 24 breast cancer patients later had thyroid cancer.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More